News

€106m to get the most from biomass
Enlarge image

BioeconomyEU

€106m to get the most from biomass

26.08.2015 - In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

The Bio-Based Industries Joint Undertaking (BBI JU) aims to research innovative ways of using renewable resources. For its second call for proposals, the partnership has released €106m. “The call for proposals is aimed at speeding up the development of new biorefineries. Moreover, it is focused on exploiting synergies across sectors. This means new business models that integrate economic actors all along the entire value chain,” the BBI said in their statement.

The bulk of the budget for the proposals will go to Demonstration Action, focusing on intermediary and end products made from biological sources. The rest will go to fundamental research and innovation in biorefinery technology. One of the challenges being tackled is pre-treating lingocellulose while removing contaminants and separating lignin and cellulosic fractions. “Solving this challenge will remove a major hurdle to processing biomass into feedstock,” BBI commented. Another project seeks to engineer a tree species that will generate wood specifically designed for industrial processing. And yet another aims to bring down the extraction and conversion costs for resources obtained from algae and microalgae.

The deadline for proposal submission is December 2015. The first call worth €100m focused on flagships and runs until mid-September. BBI JU was launched in July 2014 as a €3.7bn public-private partnership between the EU and the Bio-based Industries Consortium. 


© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2015-03/second-call-for-proposals-from-the-bio-based-industries-joint-undertaking.html

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/5.html

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • KARO BIO (S)33.00 SEK2042.86%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • SERODUS (N)2.92 NOK14.51%

FLOP

  • SYNGENTA (CH)309.90 CHF-18.19%
  • ZELTIA (E)3.35 EUR-12.76%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%

TOP

  • KARO BIO (S)33.00 SEK2029.0%
  • BIOTECH PHARMACON (N)12.40 NOK32.6%
  • TRANSGENE (F)3.82 EUR32.6%

FLOP

  • WILEX (D)1.95 EUR-44.3%
  • BIONOR PHARMA (N)1.21 NOK-41.8%
  • NORDIC NANOVECTOR (N)19.40 NOK-28.7%

TOP

  • KARO BIO (S)33.00 SEK3924.4%
  • ADOCIA (F)82.74 EUR408.9%
  • GALAPAGOS (B)53.36 EUR319.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.87 EUR-76.1%
  • NEOVACS (F)0.89 EUR-74.9%

No liability assumed, Date: 27.08.2015